Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03941262
Recruitment Status : Recruiting
First Posted : May 7, 2019
Last Update Posted : January 28, 2022
Information provided by (Responsible Party):
NKGen Biotech, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : December 2022